{"product_id":"drd2-orf-cdna-lentivirus-bhv19400197","title":"DRD2 ORF cDNA Lentivirus","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc ul{margin:0 0 12px 22px}.bhp-desc li{margin:0 0 6px}\u003c\/style\u003e\n\u003ch2\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eDRD2 encodes the dopamine receptor D2, a G protein-coupled receptor that mediates the actions of the neurotransmitter dopamine. As a member of the D2-like receptor family, it couples primarily to inhibitory Gi\/o proteins, reducing intracellular cyclic AMP and modulating ion channel activity and downstream signaling. DRD2 is expressed in brain regions controlling movement, motivation, reward, and neuroendocrine function, and it acts both postsynaptically and as a presynaptic autoreceptor regulating dopamine release. The receptor is a principal target of antipsychotic drugs and is implicated in schizophrenia, Parkinson disease, addiction, and prolactin regulation, making DRD2 an important subject in neuroscience and pharmacology research.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eProduct Description \u0026amp; Applications\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThe DRD2 ORF cDNA Lentivirus enables stable overexpression of human dopamine receptor D2 in mammalian cells. Lentiviral particles are packaged with an expression vector encoding the DRD2 open reading frame driven by a CMV promoter, delivered through a third-generation, VSV-G pseudotyped system. Depending on configuration, the construct may include a C-terminal epitope tag, a fluorescent reporter (such as EGFP or mCherry), and an antibiotic selection marker (Blasticidin or Puromycin), with tag, reporter, and selection elements linked by self-cleaving peptide sequences to allow independent translation. Stable polyclonal cell lines are readily established by antibiotic selection or fluorescence-based sorting. Supplied as high-titer particles purified by PEG precipitation and sucrose gradient centrifugation, the product transduces primary and difficult-to-transfect cells for gain-of-function studies of DRD2 in receptor signaling and pharmacology.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eAbout This Product\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThis ORF cDNA lentivirus enables stable overexpression of DRD2 (NCBI Accession: NM_000795) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (CMV). Reporter and selection marker components (EGFP, GFP, mCherry, RFP; Blasticidin, Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.\u003c\/p\u003e\n\u003cp\u003eUltra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"LipExoGen Biotech","offers":[{"title":"CMV-DRD2-V5 \/ GFP\/none \/ 3x10^6","offer_id":53251616932205,"sku":"LCV-0045-001","price":695.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/drd2-orf-cdna-lentivirus-bhv19400197","provider":"BioHippo","version":"1.0","type":"link"}